

2021 Publications:

- Aleppo G, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, Pop-Busui R, Philis-Tsimikas A, Bao S, Umpierrez G, Davis G, Kruger D, Bhargava Z, Young L, Buse JB, McGill JB, Martens T, Nguyen QT, Orozco I, Biggs W, Lucas KJ, Polonsky WH, Price D, Bergenstal RM; MOBILE Study Group (2021). The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. *Diabetes Care*, 44, 2729-2737.
- Edwards S, He X, Wang W, Poon JL, Meadows E, Price D, Johnson J, Wolpert H, Polonsky W (2021). Use of connected pen as a diagnostic tool to evaluate missed bolus dosing behavior in people with type 1 and type 2 diabetes. *Diabetes Technol Ther*, doi: 10.1089/dia.2021.0239.
- Evans M, Engberg S, Faurby M, Fernandes JDDR, Hudson P, Polonsky W (2021). Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: a systematic literature review. *Diabetes Obes Metab*, doi: 10.1111/dom.14603.
- Farooqi A, Gillies C, Sathanapally H, Abner S, Seidu S, Davies MJ, Polonsky WH, Khunti K (2021). A systematic review and meta-analysis to compare the prevalence of depression between people with and without type 1 and type 2 diabetes. *Prim Care Diabetes*, doi: 10.1016/j.pcd.2021.11.001.
- Fisher L, Fortmann AL, Florissi C, Stoner K, Knaebel J, Stuhr A (2021). How frequently and for how long do adults with type 2 diabetes use management apps? The REALL study. *J Diabetes Sci Technol*, doi: 10.1177/19322968211058766.
- Gilbert TR, Noar A, Blalock O, Polonsky WH (2021). Change in hemoglobin A1c and quality of life with real-time continuous glucose monitoring use by people with insulin-treated diabetes in the Landmark Study. *Diabetes Technol Ther*, 23, S35-S39.
- Hessler D, Strycker L, Fisher L (2021). Reductions in management distress following a randomized distress intervention are associated with improved diabetes behavioral and glycemic outcomes over time. *Diabetes Care*, 44, 1472-1479.
- Kjaer PH, Fisher L, Potter MB, Dedhia M, Parra J, Ejlskjaer N, Skovlund S, Hessler D (2021). Examining variations in action plan quality among adults with type 2 diabetes in primary care. *J Am Board Fam Med*, 34, 608-617.
- Martens T, Beck RW, Bailey R, Ruedy KJ, Calhoun P, Peters AL, Pop-Busui R, Philis-Tsimikas A, Bao S, Umpierrez G, Davis G, Kruger D, Bhargava A, Young L, McGill JB, Aleppo G, Nguyen QT, Orozco I, Biggs W, Lucas KJ, Polonsky WH, Buse JB, Price D, Bergenstal RM; MOBILE Study Group (2021). Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. *JAMA*, 325, 2262-2272.
- Oser TK, Litchman ML, Allen NA, Kwan BM, Fisher L, Jortberg BT, Polonsky WH, Oser SM (2021). Personal continuous glucose monitoring use among adults with type 2 diabetes: clinical efficacy and economic impacts. *Curr Diab Rep*, doi: 10.1007/s11892-021-01408-1.
- Polonsky WH, Arora R, Faurby M, Fernandes J, Liebl A (2021). Higher rates of persistence and adherence in patients with type 2 diabetes initiating once-weekly vs daily injectable glucagon-like peptide-1 receptor agonists in us clinical practice (STAYstudy). *Diabetes Ther*, doi: 10.1007/s13300-021-01189-6.
- Polonsky WH, Fisher L, Hessler D, Desai U, King SB, Perez-Nieves M (2021). Toward a more comprehensive understanding of the emotional side of type 2 diabetes: A re-envisioning of the assessment of diabetes distress. *J Diabetes Complications*, doi: 10.1016/j.jdiacomp.2021.108103.
- Polonsky W, Gamble C, Iyer N, Martin M, Hamersky C (2021). Exploring why people with type 2 diabetes do or do

not persist with glucagon-like peptide-1 receptor agonist therapy: a qualitative study. *Diabetes Spectrum*, 34, 175-183.

Polonsky WH, Fortmann AL, Price D, Fisher L (2021). "Hyperglycemia aversiveness": investigating an overlooked problem among adults with type 1 diabetes. *J Diabetes Complications*, doi: 10.1016/j.jdiacomp.2021.107925.

Polonsky WH (2021). Tedious, tiresome and dull: an unrecognized problem that we can solve. *Diabetes Spectrum*, 34, 85-89.

Snoek FJ, Fisher L, Polonsky WH, Stuckey H, Hessler D, Tang T, Hermanns N, Mundet X, Silva M, Sturt J, Okazaki K, Hadjiyianni I, Desai U, Perez-Nieves M (2021). Overcoming psychological insulin resistance: a practical guide for healthcare professionals. *Prim Care Diabetes*, 15, 619-621.

Uzoigwe C, Radin M, Hamersky CM, DeKoven M, Holt C, Karkare S, Polonsky WH (2021). Quality of life in patients with type 2 diabetes after switching to insulin degludec: results from a cross-sectional survey. *Qual Life Res*, 30, 1629-1640.

Wolpert H, Polonsky W, Rodbard D (2021). Insulin metrics: need for development of consensus standards for reporting of insulin dosing data. *Diabetes Technol Ther*, doi: 10.1089/dia.2020.0631.

2021 Poster Presentations:

Hood KK, Polonsky WH, Macleish SA, Levy CJ, Huyett LM, Vienneau T, Trang T.LY (2021). Youth with type 1 diabetes and their parents report improved quality of life with the Omnipod 5 automated insulin delivery system. Poster 71-OR, presented at the (virtual) Scientific Sessions of the American Diabetes Association, Chicago, IL.

Levy CJ, Polonsky WH, Hood KK, Macleish SA, Levy CJ, Huyett LM, Vienneau T, Trang T.LY (2021). 704-P - Adults with type 1 diabetes report improved quality of life with the Omnipod 5 automated insulin delivery system. Poster 704-LB, presented at the (virtual) Scientific Sessions of the American Diabetes Association, Chicago, IL.

Liebl A, Arora R, Faurby M, Diago da Rocha Fernandes J, Polonsky WH (2021). Adherence and persistence in patients with t2d initiating once-weekly vs. once-daily injectable GLP-1RA in US. clinical practice: STAY Study. Poster 83-LB, presented at the (virtual) Scientific Sessions of the American Diabetes Association, Chicago, IL.

Liu J, Poon J-L, Bispham J, Perez-Neives M, Hughes A, Chapman K, Mitchell B, Snoek F, Fisher L (2021). Validation of fear of hypoglycaemia screener: results from the T1D Exchange Registry. Abstract 161, presented at the (virtual) European Association for the Study of Diabetes Annual Meeting.

Macleish SA, Polonsky WH, Hood KK, Levy CJ, Huyett LM, Vienneau T, Trang T.LY (2021). Improved satisfaction and perceived usability with the Omnipod 5 automated insulin delivery system compared with prior therapy. Poster 709-P, presented at the (virtual) Scientific Sessions of the American Diabetes Association, Chicago, IL.

Polonsky WH, Fisher L, Hessler DM, King SB, Desai U, Kirson N, Perez-Nieves M (2021). Reimagining the assessment of diabetes distress in type 2 diabetes. Poster 560-P, presented at the (virtual) Scientific Sessions of the American Diabetes Association, Chicago, IL.

Polonsky WH, McCrimmon RJ, Whitmire KH, Giorgino F, Chen J-F, Nichols C, Lew E, Alvarez A, Coudert M, Rosenstock J (2021). Improved treatment perceptions with iglarixi vs. premix insulin in type 2 diabetes uncontrolled on basal insulin + oral antihyperglycemic drugs: patient-reported outcomes (PROs) of the SOLOMIX trial. Poster 747-P, presented at the (virtual) Scientific Sessions of the American Diabetes Association, Chicago, IL.

Wood R, Florissi C, Younge M, Stoner KC, Fisher L, Knaebel J, Lu CT, Stuhr A (2021). Real-World Evidence of Diabetes App Use in Daily Life: Assessing New Users' Engagement with a Blood Glucose Meter App over a Four-

Month Period. Poster 629-P, presented at the (virtual) Scientific Sessions of the American Diabetes Association, Chicago, IL.